Dir
Arthur F. Golden is a veteran corporate advisor and attorney appointed as a Director on the Board of Turn Therapeutics Inc. (NASDAQ: TTRX), a clinical-stage biotechnology company focused on dermatology, wound care, and infectious disease therapies[[1]](https://www.pharmanow.live/latest-news/turn-therapeutics-golden-board)[[2]](https://www.quiverquant.com/news/Turn+Therapeutics+Inc.+Begins+Trading+on+NASDAQ+and+Strengthens+Leadership+with+Key+Appointments+and+Strategic+Partnership). He joined the Board in October 2025 to strengthen governance, strategy, and growth amid the company's NASDAQ listing and clinical advancements[[1]](https://www.pharmanow.live/latest-news/turn-therapeutics-golden-board)[[2]](https://www.quiverquant.com/news/Turn+Therapeutics+Inc.+Begins+Trading+on+NASDAQ+and+Strengthens+Leadership+with+Key+Appointments+and+Strategic+Partnership).
Golden brings over 40 years of experience as a partner at Davis Polk & Wardwell LLP, where he advised Fortune 500 companies and emerging enterprises on M&A, governance, litigation, and risk management across life sciences, healthcare, and other sectors; he currently serves as Senior Counsel there[[1]](https://www.pharmanow.live/latest-news/turn-therapeutics-golden-board)[[3]](https://www.investing.com/news/insider-trading-news/turn-therapeutics-director-golden-buys-100k-in-shares-93CH-4306469). His career highlights include a 24-year tenure on the Board of Emerson Electric, chairing the Corporate Governance and Finance Committees and serving on the Executive Committee[[1]](https://www.pharmanow.live/latest-news/turn-therapeutics-golden-board)[[3]](https://www.investing.com/news/insider-trading-news/turn-therapeutics-director-golden-buys-100k-in-shares-93CH-4306469). As a TTRX insider, he has made notable purchases, including 20,202 shares on October 23, 2025, at $4.95 (totaling ~$100,000), and 20,532 shares on November 21, 2025, owning approximately 60,602 shares as of early 2026[[3]](https://www.investing.com/news/insider-trading-news/turn-therapeutics-director-golden-buys-100k-in-shares-93CH-4306469)[[5]](https://www.tradingview.com/news/tradingview:b70d351d77d77:0-turn-therapeutics-director-arthur-f-golden-acquires-20-532-shares/)[[6]](https://www.gurufocus.com/insider/11914/arthur-f-golden)[[7]](https://www.otcmarkets.com/stock/TTRX/disclosure).
View full insider profile →